Michael Cherny
Stock Analyst at B of A Securities
(3.99)
# 604
Out of 5,031 analysts
118
Total ratings
55.56%
Success rate
10.66%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $785 → $850 | $786.00 | +8.14% | 15 | Sep 24, 2025 | |
| PINC Premier | Maintains: Underperform | $19 → $21 | $28.00 | -25.00% | 10 | Aug 19, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $156.41 | +18.92% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $19.34 | +44.78% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.37 | +118.98% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $19.96 | +15.23% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $528.07 | -37.51% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $49.78 | -19.65% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $82.52 | -9.11% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $67.57 | +33.20% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $130.45 | +114.64% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $189.51 | -8.18% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $62.98 | +33.38% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $204.55 | +21.24% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $185.09 | +37.77% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.51 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $324.69 | -15.30% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $285.94 | -9.07% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $3.83 | +108.88% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.97 | +58.73% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $8.53 | +99.30% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $4.40 | +1,093.18% | 2 | Jan 5, 2022 |
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $786.00
Upside: +8.14%
Premier
Aug 19, 2025
Maintains: Underperform
Price Target: $19 → $21
Current: $28.00
Upside: -25.00%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $156.41
Upside: +18.92%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $19.34
Upside: +44.78%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.37
Upside: +118.98%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $19.96
Upside: +15.23%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $528.07
Upside: -37.51%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $49.78
Upside: -19.65%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $82.52
Upside: -9.11%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $67.57
Upside: +33.20%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $130.45
Upside: +114.64%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $189.51
Upside: -8.18%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $62.98
Upside: +33.38%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $204.55
Upside: +21.24%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $185.09
Upside: +37.77%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.51
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $324.69
Upside: -15.30%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $285.94
Upside: -9.07%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $3.83
Upside: +108.88%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.97
Upside: +58.73%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $8.53
Upside: +99.30%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $4.40
Upside: +1,093.18%